PS Label Claims Review: US Structure-Function Rules | Nutranexa

Label claims are the most visible compliance surface on any phosphatidylserine product — and the easiest to get wrong. The ingredient itself may arrive with clean specifications and full documentation, yet a single sentence on the label can convert a lawful structure-function claim into an unapproved disease claim. For US brands, the review of claim language is not a marketing formality; it is a regulatory control point that procurement and quality teams share with brand and legal. This guide walks through the label elements every PS product needs, the notification mechanics behind structure-function claims, and a practical review workflow for claim language that arrives from suppliers, agencies, or co-packers.

The Anatomy of a Compliant US PS Label

A dietary supplement label sold in the United States must carry several mandatory elements, and reviewing them in order catches most problems before print:

Identity statement. The label must state that the product is a supplement, using the term "supplement" (or a specific term such as "herbal supplement") in the statement of identity.

Net quantity, directions, and housekeeping elements. Net quantity of contents, supplement facts, ingredient list, and the name and place of business of the manufacturer, packer, or distributor must all be present with the required prominence.

Supplement Facts panel. Governed by 21 CFR 101.36, the panel lists serving size, the PS amount per serving with its source identity (for example, "Phosphatidylserine (from sunflower lecithin)"), and other dietary ingredients. Amounts must match the formulation, and the panel format follows the regulation's layout rules closely enough that deviations are visible to any trained reviewer.

Allergen labeling. When PS is soy-derived, the soy source must be declared under the Food Allergen Labeling and Consumer Protection Act's requirements for ingredients that contain or are derived from major food allergens. Sunflower-derived material removes the soy allergen declaration, which is one practical reason brands specify it — but the label must then accurately reflect the source actually used.

Structure-function disclaimer. Any structure-function claim must carry the FDA disclaimer, verbatim in substance: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Placement and prominence requirements apply.

Structure-Function Claims: What They Are and How Notification Works

A structure-function claim describes the effect of a dietary ingredient on the normal structure or function of the body — "phosphatidylserine supports memory and cognitive function" is the classic example for this ingredient. Three mechanics matter:

Notification. Under 21 CFR 101.93, the manufacturer must notify FDA no later than 30 days after first marketing the product bearing the claim. The notification identifies the product and the claim text. It is a filing, not an approval — FDA does not pre-clear the wording.

Substantiation file. The person notifying must have substantiation that the claim is truthful and not misleading, and must make that substantiation available to FDA on request. In practice this means a claim substantiation dossier: the cited human and scientific evidence for PS and cognition, mapped to the exact claim wording and the product's dose and form.

Disclaimer. Every structure-function claim on the label triggers the disclaimer requirement above, in immediate proximity to the claim or at the end of the information block, per the regulation's layout rules.

Two adjacent claim families are worth distinguishing: nutrient content claims follow different rules and generally apply to recognized nutrients rather than phospholipid classes, while health claims characterize a substance-disease relationship and require FDA authorization — no such pathway is typically available for a PS cognition claim.

The Disease-Claim Boundary: Where PS Claims Go Wrong

The line between a structure-function claim and a disease claim is the single most common failure point for cognitive-health ingredients. FDA's guidance and enforcement practice draw the boundary roughly as follows:

• Permissible: claims about normal function — memory, focus, attention, mental clarity — phrased as support rather than treatment.
• Impermissible without authorization: claims to diagnose, mitigate, treat, cure, or prevent disease, including named conditions ("Alzheimer's," "ADHD"), implicit disease references through recognized symptom pairs, and citations of literature framed as clinical proof of treatment.

References to age-associated cognitive decline sit close enough to disease framing that regulators routinely flag them; a conservative brand positions claims around supporting normal memory and cognitive function at any age.

Marketing context counts. Under FDA and FTC practice, the whole commercial impression — product name, images, testimonials, website copy — can convert an acceptable label sentence into an unlawful claim. The review should cover the label and the claims environment around it, not the sentence in isolation.

Substantiation: The File Behind Every Sentence

The FTC's truth-in-advertising standard requires competent and reliable scientific evidence to substantiate claims before they are made — a standard that reaches label claims through advertising enforcement even though FDA does not pre-approve the wording. A working PS substantiation file contains:

• The claim text as it will appear, plus every variant used in marketing.
• The scientific evidence relied on: human studies, reviews, and safety literature, with a note of the doses and forms studied relative to your product.
• A written gap analysis where the claim language and the evidence base differ — for example, evidence at 300 mg/day supporting a claim on a 100 mg/day product is a known review flag.
• The FDA notification copy and confirmation of the disclaimer's use.

Procurement's role is upstream: when a supplier offers "claim language" as part of an ingredient sales package, treat it as a starting draft, not as substantiation. The claim burden attaches to the finished product and the brand, not the ingredient seller.

Reviewing Supplier Claim Language Before It Reaches Your Artwork

A five-step review keeps supplier-provided claims from becoming brand liabilities:

1. Classify each sentence: structure-function, content claim, health claim, or disease claim. Anything in the last two categories goes back.
2. Check the source statement and allergen declaration against the material actually purchased — a claim drafted for soy PS will be wrong for sunflower PS.
3. Verify the dose and form in the claim's supporting evidence match the product specification.
4. Confirm the disclaimer, notification timing (within 30 days of first marketing), and Supplement Facts panel consistency.
5. Archive the substantiation file, the notification, and the final artwork version together, so the record is retrievable at audit or dispute time.

Preguntas frecuentes

Do I need FDA approval before using a structure-function claim for phosphatidylserine?

No. Structure-function claims do not require pre-approval, but they require a notification to FDA no later than 30 days after first marketing, a substantiation file available on request, and the statutory disclaimer on the label. The legal risk lives in substantiation and claim classification, not in the filing itself.

Can my label say phosphatidylserine "reduces the risk of dementia"?

No. That is a health claim characterizing a substance-disease relationship and would require FDA authorization that does not exist for PS. Disease-related language — named conditions, treatment framing, symptom-pair imagery — converts a cognitive-support position into an unlawful disease claim.

What should appear in the Supplement Facts panel for a sunflower-derived PS?

Serving size, the amount of phosphatidylserine per serving, and its source identity (for example, "Phosphatidylserine (from sunflower lecithin)"), laid out per 21 CFR 101.36. The panel must match the formulation as produced.

Is supplier-provided claim language something I can use as-is?

Treat it as a draft at most. The substantiation obligation attaches to the finished product and the brand. Verify the claim classification, the dose and form match with the cited evidence, the allergen source statement, and the disclaimer before any sentence reaches artwork.

Does the FDA notification have to be renewed for each batch?

No. The notification is made once per product bearing the claim, within 30 days of first marketing. However, a materially new claim or a substantially different product requires its own review.

Conclusión

A compliant phosphatidylserine label is the product of three checks that happen in order: the mandatory label elements are present and correctly formatted, every claim sentence is classified and stays on the structure-function side of the line, and a substantiation file exists that matches the claim text, the dose, and the form in the bottle. None of these checks is difficult; each is commonly skipped under launch pressure. Brands that build the review into the artwork workflow and verify supplier claim language rather than inheriting it ship products that hold up to FDA scrutiny, FTC review, and retailer audits alike.

Fuentes

• US FDA — Dietary Supplements: https://www.fda.gov/food/dietary-supplements
• US FDA — Labeling and Claims for Dietary Supplements: https://www.fda.gov/food/dietary-supplements
• eCFR — Title 21, Food and Drugs: https://www.ecfr.gov/
• Federal Trade Commission — Advertising and Marketing: https://www.ftc.gov/

Próximos pasos recomendados

• Revisa el Phosphatidylserine página del producto.
• Comparar Soy PS y Sunflower PS.
• Verificar prueba de fabricación y Calidad e I+D.